CONMED Corporation (CNMD) SEC Filings & Earnings Calls
EquiReason read 17 CONMED Corporation SEC filings in the last 12 months. Latest: 10-Q on 2026-07-29 — CONMED reported Q2 2026 results with flat revenue growth, improved gross margins, and significant balance sheet restructuring..
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
- Market cap
- 1.5B
- P/E TTM
- 26.6
- Dividend yield
- 1.2%
- 52-week
- —
- Next earnings
- 28 Oct, in 4 days
Every filing, read
last 12 months · SECWhat happened, the numbers inside, guidance and risks. The original is one click away.
29 Jul 202610-QCONMED reported Q2 2026 results with flat revenue growth, improved gross margins, and significant balance sheet restructuring.earningsopen
Figures in the filing · each found in the filing text
| Net sales · Q2-2026 | $343M | +0% y/y |
| Net income · Q2-2026 | $23M | +8% y/y |
| Gross profit margin · Q2-2026 | 57.5% | |
| Diluted EPS · Q2-2026 | $0.77 | +12% y/y |
| Orthopedic Surgery Sales · Orthopedic Surgery · Q2-2026 | $152M | +8% y/y |
| General Surgery Sales · General Surgery · Q2-2026 | $191M | -5% y/y |
Risks flagged
Tariff Exposure
“our results of operations are being impacted by tariffs placed on imported goods to the United States as well as exporting of products to other countries.” · word for word
Supply Chain Challenges
“The Company has experienced higher manufacturing and operating costs as well as ongoing supply chain challenges.” · word for word
Debt Refinancing Risk
“If we are unable to service our indebtedness, we will be forced to adopt an alternative strategy that may include actions such as foregoing acquisitions, reducing or delaying capital expenditures, selling assets, restructuring or refinancing our indebtedness or seeking additional equity capital.” · word for word
29 Jul 20268-K · 2.02CONMED reported Q2 2026 sales of $343.5M (+0.3% YoY), adjusted EPS $1.38 (+20.0%), and raised FY2026 adjusted EPS guidance to $4.48-$4.60 from $4.30-$4.45, reflecting strong organic growth and tariff refund benefit.earningsopen
Figures in the filing · each found in the filing text
| Net Sales · Q2-2026 | $343M | +0% y/y |
| Gross Margin · Q2-2026 | 57.5% | |
| Adjusted Diluted EPS · Q2-2026 | $1.38 | +20% y/y |
| Diluted EPS (GAAP) · Q2-2026 | $0.77 | +12% y/y |
| Net Income · Q2-2026 | $23M | +8% y/y |
Guidance
FY26 adjusted diluted EPS raised to $4.48-$4.60 from $4.30-$4.45; FY26 net sales guidance narrowed to $1,358-$1,373M from $1,350-$1,375M; organic constant currency growth 5.0-6.0% vs prior 5.0-6.5%
FY2026 adjusted EPS guidance raised, reflecting Q2 beat and improved outlook; revenue guidance narrowed; organic constant currency growth maintained.
Risks flagged
Domestic sales declined 8.0% as reported, indicating potential market share or demand challenges in the U.S.
“Domestic sales decreased 8.0% as reported” · word for word
Strategic exit of GI product offerings may impact revenue growth in the near term.
“Excluding the impact of the Company’s previously announced strategic exits of GI product offerings” · word for word
17 Jun 20268-K · 5.02, 7.01Base salary (CFO) $650,000.00; annual cash bonus target (CFO) 85; option grant value (CFO) $575,000.00open
Figures in the filing · each found in the filing text
| base salary (CFO) · point_in_time | $650000.00 | |
| annual cash bonus target (CFO) · point_in_time | 85.0% | |
| option grant value (CFO) · point_in_time | $575000.00 | |
| RSU grant value (CFO) · point_in_time | $1M | |
| PSU grant value (CFO) · point_in_time | $575000.00 | |
| make-whole RSU grant value (CFO) · point_in_time | $2M | |
| one-time cash bonus (CFO) · point_in_time | $34750.00 |
Risks flagged
CFO transition risk; new CFO joining from outside the company.
“John E. Gallagher has been appointed to serve as the Company’s Executive Vice President, Chief Financial Officer beginning July 15, 2026” · word for word
1 Jun 20268-K · 1.01, 2.03CONMED entered into a $450M incremental senior secured delayed draw term loan facility (Term A-2) to repurchase convertible notes due 2026. Matures June 2030, SOFR+1.75% initially. Increases leverage but refinances near-term maturity.open
Figures in the filing · each found in the filing text
| Term A-2 Loan Facility principal amount · Q2-2026 | $450M |
Risks flagged
Increased secured debt and leverage from new term loan facility.
“The Term A-2 Loan Facility is secured by the same assets and rights of CONMED and certain of its subsidiaries”
20 May 20268-K · 5.02, 5.03, 5.07Reported the departure of a director or principal officer (CEO/CFO change); amended its articles of incorporation or bylawsopen
Risks flagged
No material financial or operational risks disclosed in this filing
“Filing covers routine governance changes; no financial metrics or forward guidance provided”
30 Apr 202610-QNet sales $317M (-1% y/y); Orthopedic surgery sales $148M (+7% y/y); General surgery sales $169M (-7% y/y)open
Figures in the filing · each found in the filing text
| Net sales · Q1-2026 | $317M | -1% y/y |
| Orthopedic surgery sales · Orthopedic surgery · Q1-2026 | $148M | +7% y/y |
| General surgery sales · General surgery · Q1-2026 | $169M | -7% y/y |
| Gross profit margin · Q1-2026 | 57.9% | |
| Net income · Q1-2026 | $14M | +130% y/y |
| Operating cash flow · Q1-2026 | $14M | -68% y/y |
| Single-use products sales · Q1-2026 | $270M | -2% y/y |
| Capital products sales · Q1-2026 | $47M | +5% y/y |
Risks flagged
Gastroenterology exit revenue headwind
“Gastroenterology sales were $9.5 million and $25.0 million during the three months ended March 31, 2026 and March 31, 2025, respectively.” · word for word
Operating cash flow decline
“Net cash provided by operating activities was $13.5 million and $41.5 million in the three months ended March 31, 2026 and March 31, 2025, respectively.” · word for word
Tariff uncertainty
“During the first quarter of 2026, the Supreme Court ruled tariffs paid under the International Emergency Economic Powers Act ("IEEPA") were illegal. We are following the process to submit refund claims for such payments however this requires review and approval from the U.S. Customs and Border Protection agency and therefore we have not recorded any receivab” · word for word
29 Apr 20268-K · 2.02Net sales $317M (-1% y/y); Gross profit % 57.9; Diluted EPS (GAAP) $0.45 (+137% y/y); Guidance: Organic constant currency revenue growth guidance raised from 4.5-6.0% to 5.0-6.5%; reported revenue guidance narrowed to $1.350-1.375Bearningsopen
Figures in the filing · each found in the filing text
| Net sales · Q1-2026 | $317M | -1% y/y |
| Gross profit % · Q1-2026 | 57.9% | |
| Diluted EPS (GAAP) · Q1-2026 | $0.45 | +137% y/y |
| Adjusted diluted EPS · Q1-2026 | $0.89 | -6% y/y |
| Orthopedic Surgery revenue · Orthopedic Surgery · Q1-2026 | $148M | +7% y/y |
| General Surgery revenue · General Surgery · Q1-2026 | $169M | -7% y/y |
| Domestic revenue · Domestic · Q1-2026 | $173M | -6% y/y |
| International revenue · International · Q1-2026 | $144M | +5% y/y |
| Single-use Products revenue · Single-use Products · Q1-2026 | $270M | -2% y/y |
Guidance
Organic constant currency revenue growth guidance raised from 4.5-6.0% to 5.0-6.5%; reported revenue guidance narrowed to $1.350-1.375B
Management raised organic revenue growth guidance and reaffirmed adjusted EPS, citing strong Q1 performance and momentum in higher-growth segments.
Risks flagged
GI product exit continues to pressure reported revenue; $15.5M headwind in Q1.
“Net sales growth was impacted by a $15.5 million decrease in sales from the exit of certain GI products.” · word for word
Higher interest expense from planned debt refinancing may pressure adjusted EPS.
“higher-than-previously anticipated interest expense due to the planned refinancing of the Company's debt during 2026” · word for word
7 Apr 2026DEF 14AAnnual proxy statement filed, disclosing executive compensation, governance changes, and 2025 financial results.open
Figures in the filing · each found in the filing text
| Revenue · FY2025 | $1.37B | +5% y/y |
| Net Income · FY2025 | $47M | -64% y/y |
| Adjusted Diluted EPS · FY2025 | $4.59 | +10% y/y |
| Operating Cash Flow · FY2025 | $171M | |
| Gross Margin · FY2025 | 56.4% |
Risks flagged
Stock option underwater risk
“All vested and unvested stock options held by Mr. Beyer were out-of-the money as of December 31, 2025 (stock price as of December 31, 2025: $40.60).” · word for word
PSU payout risk
“Current Performance of Outstanding PSUs for NEOs: 0% of target for 2023, 2024, and 2025 awards as of Dec 31, 2025.” · word for word
CEO transition risk
“CFO transition in progress; interim principal financial officer appointed.”
13 Mar 20268-K · 5.02Reported a director or officer change (departure, election, appointment or pay arrangement)open
Risks flagged
Interim CFO appointment may indicate temporary leadership gap.
“Appointment of interim Principal Financial Officer with no permanent successor named.”
17 Feb 202610-KNet sales $1.37B (+5% y/y); Operating cash flow $171M (+2% y/y); Gross margin 54.6open
Figures in the filing · each found in the filing text
| Net sales · FY2025 | $1.37B | +5% y/y |
| Operating cash flow · FY2025 | $171M | +2% y/y |
| Gross margin · FY2025 | 54.6% | |
| Orthopedic surgery sales · Orthopedic surgery · FY2025 | $575M | +6% y/y |
| General surgery sales · General surgery · FY2025 | $800M | +5% y/y |
| Single-use products sales · Single-use products · FY2025 | $1.18B | +6% y/y |
| Capital products sales · Capital products · FY2025 | $191M | -2% y/y |
| Interest expense · FY2025 | $31M | -17% y/y |
| Capital expenditures · FY2025 | $20M | +51% y/y |
| Cash and cash equivalents · FY2025 | $41M |
Risks flagged
Leverage and debt service risk
“a portion of our cash flow from operations must be dedicated to debt service and will not be available for operations, capital expenditures, acquisitions, dividends, share repurchases and other purposes” · word for word
Interest rate risk on variable debt
“Our variable rate indebtedness subjects us to interest rate risk, which could cause our debt service obligations to increase significantly.” · word for word
Acquisition integration risk
“Our financial performance is subject to the risks inherent in any acquisition, including the effects of increased borrowing and integration of newly acquired businesses or product lines.” · word for word
Divestiture risk
“Our financial performance is subject to risks in connection with divestitures, and our failure to manage these divestitures could have a negative impact on our business.” · word for word
Cybersecurity breach risk
“We could experience a failure of a key information technology system, process or site or a breach of information security, including a cybersecurity breach or failure of one or more key information technology systems” · word for word
28 Jan 20268-K · 2.02Net Sales $373M (+8% y/y); Diluted Net Earnings Per Share (GAAP) $0.54 (-50% y/y); Adjusted Diluted Net Earnings Per Share $1.43 (+7% y/y); Guidance: FY2026 revenue $1.345-1.375B, adjusted EPS $4.30-4.45earningsopen
Figures in the filing · each found in the filing text
| Net Sales · Consolidated · Q4-2025 | $373M | +8% y/y |
| Diluted Net Earnings Per Share (GAAP) · Consolidated · Q4-2025 | $0.54 | -50% y/y |
| Adjusted Diluted Net Earnings Per Share · Consolidated · Q4-2025 | $1.43 | +7% y/y |
| Gross Profit · Consolidated · Q4-2025 | $218M | +10% y/y |
| Income from Operations · Consolidated · Q4-2025 | $37M | -30% y/y |
| Orthopedic Surgery Sales · Orthopedic Surgery · Q4-2025 | $157M | +13% y/y |
| General Surgery Sales · General Surgery · Q4-2025 | $216M | +4% y/y |
| Domestic Revenue · Domestic · Q4-2025 | $206M | +1% y/y |
| International Revenue · International · Q4-2025 | $167M | +17% y/y |
| Single-use Products Sales · Single-use Products · Q4-2025 | $321M | +8% y/y |
Guidance
FY2026 revenue $1.345-1.375B, adjusted EPS $4.30-4.45
Provides FY2026 guidance with organic constant currency growth of 4.5-6% and adjusted EPS growth.
Risks flagged
GAAP EPS decline due to higher operating expenses and tax provision
“Diluted EPS (GAAP) decreased 50% to $0.54; income from operations margin declined to 9.8% from 15.2%.”
12 Jan 20268-K · 7.01Revenue $1.37B; Adjusted diluted EPS $4.48; Guidance: FY2026 revenue growth 4-8%, adjusted EPS $4.48-$4.53open
Figures in the filing · each found in the filing text
| Revenue · FY2026 | $1.37B | |
| Adjusted diluted EPS · FY2026 | $4.48 |
Guidance
FY2026 revenue growth 4-8%, adjusted EPS $4.48-$4.53
Preliminary 2026 guidance indicates revenue growth acceleration and adjusted EPS improvement.
8 Jan 20268-K · 5.02Reported the departure of a director or principal officer (CEO/CFO change); filed financial statements and exhibits with this reportopen
Risks flagged
CFO transition may disrupt financial operations and investor confidence.
“CFO separation; consulting period through November 2026; search for new CFO.”
5 Dec 20258-K · 7.01Gastroenterology gross margin 45; Guidance: Revenue $1.365B-$1.372B; adjusted EPS $4.48-$4.53open
Figures in the filing · each found in the filing text
| Gastroenterology gross margin · Gastroenterology · FY2025 | 45.0% |
Guidance
Revenue $1.365B-$1.372B; adjusted EPS $4.48-$4.53
Reaffirmed 2025 revenue and EPS guidance; exit improves margin profile.
Risks flagged
EPS dilution of $0.45-$0.55 in 2026 from exit; revenue loss of $90M-$95M.
“EPS dilution of $0.45–$0.55 in 2026... revenue $90 million to $95 million in 2025.” · word for word
6 Nov 202510-QQuarterly report with revenue growth but significant gross margin compression and inventory write-offs.earningsopen
Figures in the filing · each found in the filing text
| Gross profit margin · Q3-2025 | 49.2% | |
| Gross profit margin · 9M-2025 | 53.1% | |
| Net income · 9M-2025 | $30M | -69% y/y |
| Net cash provided by operating activities · 9M-2025 | $124M | +1% y/y |
| Capital expenditures · 9M-2025 | $15M | +63% y/y |
| Weighted average interest rate on borrowings · Q3-2025 | 2.8% |
Risks flagged
Significant gross margin compression
“Gross profit margins decreased 730 basis points to 49.2% in the three months ended September 30, 2025 as compared to 56.5% in the three months ended September 30, 2024.” · word for word
Inventory write-offs and product discontinuations
“As a result of our consultations and internal review, we wrote off $19.7 million in inventory, equipment, tooling and patents related to the cancellation of planned new product lines and discontinuation of certain catalog numbers during the three and nine months ended September 30, 2025.” · word for word
Loss of VIABIL distribution agreement after 2026
“CONMED will not be renewing its Distribution Agreement for the commercial support and distribution of the Gore® VIABIL® device after December 31, 2026. The VIABIL distribution represented $44.1 million of net sales in the nine months ending September 30, 2025, with a gross profit margin of approximately 38%.” · word for word
Inflationary and tariff cost pressures
“The Company has been and continues to be impacted by the macro-economic environment and we are experiencing higher manufacturing and operating costs caused by inflationary pressures and ongoing supply chain challenges.” · word for word
High SG&A expense ratio
“Selling and administrative expense as a percentage of net sales increased 1,000 basis points to 41.5% in the three months ended September 30, 2025 as compared to 31.5% in the three months ended September 30, 2024.” · word for word
5 Nov 20258-K · 2.02Net sales $338M (+7% y/y); Diluted net earnings per share (GAAP) $0.09 (-94% y/y); Adjusted diluted net earnings per share $1.08 (+3% y/y); Guidance: FY2025 revenue $1.365-1.372B (prior $1.356-1.378B); adjusted EPS $4.48-4.53 (prior $4.40-4earningsopen
Figures in the filing · each found in the filing text
| Net sales · Q3-2025 | $338M | +7% y/y |
| Diluted net earnings per share (GAAP) · Q3-2025 | $0.09 | -94% y/y |
| Adjusted diluted net earnings per share · Q3-2025 | $1.08 | +3% y/y |
| Gross profit · Q3-2025 | $166M | -7% y/y |
| Gross margin · Q3-2025 | 49.2% | |
| Income from operations · Q3-2025 | $12M | -82% y/y |
| Net income · Q3-2025 | $3M | -94% y/y |
| Orthopedic Surgery sales · Orthopedic Surgery · Q3-2025 | $138M | +6% y/y |
| General Surgery sales · General Surgery · Q3-2025 | $200M | +7% y/y |
| Single-use Products sales · Q3-2025 | $289M | +7% y/y |
Guidance
FY2025 revenue $1.365-1.372B (prior $1.356-1.378B); adjusted EPS $4.48-4.53 (prior $4.40-4.55)
Revenue guidance raised; EPS guidance narrowed higher; tariff headwind acknowledged.
Risks flagged
Significant GAAP EPS decline due to cost increases and tariff impact.
“GAAP EPS $0.09 vs $1.57 YoY; gross margin down 730 bps; tariff impact estimated $0.07 in Q4.”
Dividend suspended to fund buyback; may signal cash conservation.
“Board suspended quarterly cash dividend; new $150M buyback.”
CONMED Corporation — questions
- What did CONMED Corporation file recently?
- 17 SEC filings in the last 12 months. Latest: 10-Q on 2026-07-29 — CONMED reported Q2 2026 results with flat revenue growth, improved gross margins, and significant balance sheet restructuring.
Every figure on this page comes from CONMED Corporation's own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.